Latest Capital Management News

Barton Gold Holdings reports a robust December quarter marked by a $5 million gold sale, extensive drilling at Tunkillia and Tarcoola projects, and a strong cash position heading into 2025.

Stockland updates its dividend distribution details, confirming an 8 cent per security payout and announcing the Dividend Reinvestment Plan price ahead of the February payment date.

DeSoto Resources has secured a strategic manganese project in Brazil and received pioneering drilling approvals in Australia's Northern Territory, setting the stage for significant exploration activity in 2025.

Raptis Group Limited reported a positive net cash inflow from operating activities of $54,509 for the quarter ended December 31, 2024, ending with $303,102 in cash and equivalents. The company recorded no investing or financing cash flows during the period.

IPB Petroleum has appointed a new chairman and is intensifying efforts to secure funding for drilling its key Browse Basin assets, while maintaining a strong cash position and exploring new project opportunities.

CD Private Equity Fund II has announced a special unfranked dividend of AUD 0.09 per ordinary unit, payable on February 24, 2025, signaling steady returns for investors.

SportsHero Limited has arranged a $1 million unsecured loan facility to support its working capital needs, with flexible monthly drawdowns and a fixed 10% interest rate. The company has already drawn $100,000 from this facility, signaling ongoing liquidity management efforts.

Australian Rare Earths Limited has secured a $5 million government grant to advance its Koppamurra Rare Earths Project, while initial drilling at its Overland Uranium Project validates promising geological models for uranium deposits.

InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.

Vonex Limited reports solid operational improvements and customer satisfaction in Q2 FY25, while endorsing Maxo Telecommunications’ takeover offer and planning a $13 million capital raise to manage debt.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

Orpheus Uranium Limited reports a productive December quarter marked by a successful $1.66 million capital raise, completion of a major gravity survey at Mount Douglas, and ongoing progress toward regulatory approvals for advanced uranium exploration.